These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 15797656)
1. Risk reduction therapy for syndrome X: comparison of several treatments. Oron-Herman M; Sela BA; Rosenthal T Am J Hypertens; 2005 Mar; 18(3):372-8. PubMed ID: 15797656 [TBL] [Abstract][Full Text] [Related]
2. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469 [TBL] [Abstract][Full Text] [Related]
3. Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats. Si X; Webb RC; Richey JM Can J Physiol Pharmacol; 1999 Oct; 77(10):755-62. PubMed ID: 10588479 [TBL] [Abstract][Full Text] [Related]
5. Hepatic effects of rosiglitazone in rats with the metabolic syndrome. Ackerman Z; Oron-Herman M; Pappo O; Peleg E; Safadi R; Schmilovitz-Weiss H; Grozovski M Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):663-8. PubMed ID: 20210788 [TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model. St-Pierre P; Bouffard L; Maheux P Biochem Pharmacol; 2004 May; 67(10):1997-2004. PubMed ID: 15130775 [TBL] [Abstract][Full Text] [Related]
7. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Ackerman Z; Oron-Herman M; Grozovski M; Rosenthal T; Pappo O; Link G; Sela BA Hypertension; 2005 May; 45(5):1012-8. PubMed ID: 15824194 [TBL] [Abstract][Full Text] [Related]
8. The effects of S-allylmercaptocaptopril, the synthetic product of allicin and captopril, on cardiovascular risk factors associated with the metabolic syndrome. Oron-Herman M; Rosenthal T; Mirelman D; Miron T; Rabinkov A; Wilchek M; Sela BA Atherosclerosis; 2005 Dec; 183(2):238-43. PubMed ID: 16285991 [TBL] [Abstract][Full Text] [Related]
9. (+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats. Banz WJ; Davis J; Steinle JJ; Adler S; Oitker J; Winters TA; Higginbotham DA; Hou Y; Henry N; Peterson R; Meyers CY Obes Res; 2005 Nov; 13(11):1915-24. PubMed ID: 16339123 [TBL] [Abstract][Full Text] [Related]
10. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533 [TBL] [Abstract][Full Text] [Related]
11. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Rivera L; Morón R; Sánchez M; Zarzuelo A; Galisteo M Obesity (Silver Spring); 2008 Sep; 16(9):2081-7. PubMed ID: 18551111 [TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. Fernandes-Santos C; Evangelista Carneiro R; de Souza Mendonca L; Barbosa Aguila M; Mandarim-de-Lacerda CA Pancreas; 2009 Apr; 38(3):e80-6. PubMed ID: 19214135 [TBL] [Abstract][Full Text] [Related]
13. Metabolic stress with a high carbohydrate diet increases adiponectin levels. Kamari Y; Grossman E; Oron-Herman M; Peleg E; Shabtay Z; Shamiss A; Sharabi Y Horm Metab Res; 2007 May; 39(5):384-8. PubMed ID: 17533582 [TBL] [Abstract][Full Text] [Related]
14. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639 [TBL] [Abstract][Full Text] [Related]
15. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382 [TBL] [Abstract][Full Text] [Related]
16. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U; Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186 [TBL] [Abstract][Full Text] [Related]
17. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. Sharma AM; Wagner T; Marsalek P J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705 [TBL] [Abstract][Full Text] [Related]
18. Aqueous extract of Monascus purpureus M9011 prevents and reverses fructose-induced hypertension in rats. Hsieh PS; Tai YH J Agric Food Chem; 2003 Jul; 51(14):3945-50. PubMed ID: 12822928 [TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome: comparison of the two commonly used animal models. Oron-Herman M; Kamari Y; Grossman E; Yeger G; Peleg E; Shabtay Z; Shamiss A; Sharabi Y Am J Hypertens; 2008 Sep; 21(9):1018-22. PubMed ID: 18566592 [TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]